Company intelligence / Profile preview

Syenex

Evanston, Illinois, United Statessyenex.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Syenex has developed advanced synthetic biology platforms to improve the efficiency and scalability of gene and cell therapy delivery vehicles. Their technologies are designed to accelerate the development of curative therapies by providing best-in-class targeted delivery systems. No clinical trial results are available yet as they primarily serve as an enabling technology provider for other developers.[1][2][4]

Therapeutic areas: Oncology
Modalities: Gene therapiesCell therapiesExtracellular vesicles (EVs)Engineered viral vectors (e.g., lentiviral, retroviral)[2][3][5]
Industry: Drug Discovery Services

Partnerships

CTMC (joint venture between MD Anderson Cancer Center and Resilience) – partnership to advance T cell therapy manufacturing using Syenex’s SNX-T1 and SNX-T2 vector systems[5].

Beyond the preview

Go deeper on Syenex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syenex.

Explore the full profile